Hudson Executive Capital LP 13D and 13G filings for Akoya Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-07 4:30 pm Sale |
2023-02-03 | 13D | Akoya Biosciences, Inc. AKYA |
Hudson Executive Capital LP | 1,892,204 4.990% |
-555,354 (-22.69%) |
Filing |
| 2022-12-02 4:15 pm Sale |
2022-11-30 | 13D | Akoya Biosciences, Inc. AKYA |
Hudson Executive Capital LP | 2,447,558 6.400% |
-1,250,000 (-33.81%) |
Filing |
| 2022-09-13 4:10 pm Purchase |
2022-09-09 | 13D | Akoya Biosciences, Inc. AKYA |
Hudson Executive Capital LP | 3,697,558 9.800% |
1,617,015 (+77.72%) |
Filing |
| 2021-10-18 4:02 pm Purchase |
2021-10-06 | 13D | Akoya Biosciences, Inc. AKYA |
Hudson Executive Capital LP | 2,080,543 5.600% |
2,080,543 (New Position) |
Filing |